Last $2.93 USD
Change Today -0.02 / -0.68%
Volume 80.0K
CLSN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 5:20 PM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

celsion corp (CLSN) Snapshot

Open
$2.92
Previous Close
$2.95
Day High
$2.95
Day Low
$2.91
52 Week High
10/24/13 - $5.90
52 Week Low
04/15/14 - $2.82
Market Cap
58.5M
Average Volume 10 Days
67.9K
EPS TTM
$-1.30
Shares Outstanding
20.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELSION CORP (CLSN)

celsion corp (CLSN) Related Bloomberg News

View More Bloomberg News

celsion corp (CLSN) Related Businessweek News

No Related Businessweek News Found

celsion corp (CLSN) Details

Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; under Phase II clinical trials for recurrent chest wall breast cancer; and in phase II clinical trials for colorectal liver metastasis. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

13 Employees
Last Reported Date: 03/13/14
Founded in 1982

celsion corp (CLSN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $434.1K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $275.2K
Chief Medical Officer and Vice President
Total Annual Compensation: $328.5K
Compensation as of Fiscal Year 2013.

celsion corp (CLSN) Key Developments

Celsion Corp. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Celsion Corp. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Celsion Corporation Announces Data from Two Phase I Studies on ThermoDox in Recurrent Chest Wall Breast Cancer Publish in the International Journal of Hyperthermia

Celsion Corporation announced that data from two Phase I studies on ThermoDox(R) in recurrent chest wall breast cancer were published in the International Journal of Hyperthermia. The article describes the combined results of the two similarly designed Phase I trials with one study conducted at Duke University and the second study conducted at other major breast cancer centers in the U.S., in which eligible patients with unresectable chest wall recurrences had progressed on the chest wall after prior hormone therapy, chemotherapy, and radiotherapy. Patients received up to six cycles of ThermoDox(R) every 21-35 days, followed immediately by chest wall mild local hyperthermia for 1 hour at 40-42degC. In the first trial, 18 subjects received ThermoDox(R) at 20, 30, or 40 mg/m(2); in the second trial, 11 subjects received ThermoDox(R) at 40 or 50 mg/m(2). The results showed that the maximum tolerated dose was 50 mg/m(2). The rate of overall local response was 48%, with five patients (17%) achieving complete local responses and nine patients (31%) having partial local responses. It was concluded that ThermoDox(R) at 50 mg/m(2) and mild local hyperthermia was safe, and this combined therapy produces objective responses in heavily pretreated RCWBC patients. Importantly, these Phase I data are consistent with the impressive interim results from Celsion's ongoing open-label Phase II DIGNITY Study of ThermoDox(R) in RCWBC. The DIGNITY Study will enroll a minimum of 20 patients at several U.S. clinical sites and is evaluating ThermoDox(R) in combination with mild hyperthermia using a treatment design equivalent to that used in the Phase I programs. Of the 13 patients enrolled and treated, 10 were eligible for evaluation of efficacy. Based on data available to date, 60% of patients experienced a stabilization of their highly refractory disease with a local response rate of 50% observed in the 10 evaluable patients, notably 3 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD).

Celsion Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Celsion Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported that loss from operations was $6,413,000 compared to $3,848,000 a year ago. Net loss attributable to the common shareholders was $6,673,000 or $0.38 per basic share compared to net loss of $421,000 or $0.03 per basic share a year ago. Licensing revenue was $125,000 compared to $125,000 a year ago. For the six months, the company reported that loss from operations was $11,615,000 compared to $8,615,000 a year ago. Net loss attributable to the common shareholders was $12,096,000 or $0.71 per basic and fully diluted share compared to $4,831,000 or $0.45 per basic and fully diluted share a year ago. Licensing revenue was $250,000 compared to $250,000 a year ago. Net cash used in operations was $9.0 million for the six months ended June 30, 2014 compared to $3.4 million in the same prior year period. This increase of $5.6 million was due to a $5 million payment from the company's Chinese collaborator, Zhejiang Hisun Pharmaceutical Company, received in January 2013 for a non-refundable technology transfer fee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLSN:US $2.93 USD -0.02

CLSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BSD Medical Corp $0.55 USD +0.0085
Medifocus Inc C$0.12 CAD -0.005
View Industry Companies
 

Industry Analysis

CLSN

Industry Average

Valuation CLSN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 103.4x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELSION CORP, please visit www.celsion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.